Abe M - Search Results

1

The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2.

Higa Y, Hiasa M, Tenshin H, Nakaue E, Tanaka M, Kim S, Nakagawa M, Shimizu S, Tanimoto K, Teramachi J, Harada T, Oda A, Oura M, Sogabe K, Hara T, Sumitani R, Maruhashi T, Yamagami H, Endo I, Matsumoto T, Tanaka E, Abe M. Higa Y, et al. Among authors: abe m. Antioxidants (Basel). 2023 Jan 5;12(1):133. doi: 10.3390/antiox12010133. Antioxidants (Basel). 2023. PMID: 36670994 Free PMC article.

2

Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.

Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T. Abe M, et al. Blood. 2002 Sep 15;100(6):2195-202. Blood. 2002. PMID: 12200385 Free article.

3

Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.

Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. Hashimoto T, et al. Among authors: abe m. Br J Haematol. 2004 Apr;125(1):38-41. doi: 10.1111/j.1365-2141.2004.04864.x. Br J Haematol. 2004. PMID: 15015966 Free article.

4

[Biochemical markers in bone metastasis].

Hashimoto T, Abe M, Matsumoto T. Hashimoto T, et al. Among authors: abe m. Gan To Kagaku Ryoho. 2004 Jul;31(7):1027-33. Gan To Kagaku Ryoho. 2004. PMID: 15272580 Review. Japanese.

5

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D, Matsumoto T. Oshima T, et al. Among authors: abe m. Blood. 2005 Nov 1;106(9):3160-5. doi: 10.1182/blood-2004-12-4940. Epub 2005 Jul 19. Blood. 2005. PMID: 16030194 Free article.

6

Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma.

Jalili A, Ozaki S, Hara T, Shibata H, Hashimoto T, Abe M, Nishioka Y, Matsumoto T. Jalili A, et al. Among authors: abe m. Blood. 2005 Nov 15;106(10):3538-45. doi: 10.1182/blood-2005-04-1438. Epub 2005 Jul 21. Blood. 2005. PMID: 16037388 Free article.

7

Bone destruction in multiple myeloma.

Matsumoto T, Abe M. Matsumoto T, et al. Among authors: abe m. Ann N Y Acad Sci. 2006 Apr;1068:319-26. doi: 10.1196/annals.1346.035. Ann N Y Acad Sci. 2006. PMID: 16831932

8

Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.

Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T. Tanaka Y, et al. Among authors: abe m. Clin Cancer Res. 2007 Feb 1;13(3):816-23. doi: 10.1158/1078-0432.CCR-06-2258. Clin Cancer Res. 2007. PMID: 17289872

9

[Mechanisms for formation of myeloma bone disease].

Yata K, Abe M, Matsumoto T. Yata K, et al. Among authors: abe m. Clin Calcium. 2008 Apr;18(4):438-46. Clin Calcium. 2008. PMID: 18379024 Review. Japanese.

10

Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.

Abe M, Hiura K, Ozaki S, Kido S, Matsumoto T. Abe M, et al. J Bone Miner Metab. 2009;27(1):16-23. doi: 10.1007/s00774-008-0012-z. Epub 2008 Dec 5. J Bone Miner Metab. 2009. PMID: 19057841

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,064 results

Search Page